ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1222

Incidence and Time Trends of Malignancy in Rheumatoid Arthritis: A Population Based Study 1980-2007

Kerry Wright1, Cynthia S. Crowson2, Sherine E. Gabriel3 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Malignancy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: to determine the incidence and time trends of malignancy in patients with rheumatoid arthritis (RA) in 1980-2007 compared to individuals without RA from the same population.

Methods: A population based inception cohort of patients with RA who fulfilled 1987 ACR criteria in 1980-2007 and an age and sex matched cohort of non-RA subjects from the same population was assembled and followed until death, migration or 12/31/2008. Incidence rates of overall and site specific malignancy were collected. Cumulative incidence of malignancy adjusted for the competing risk of death was estimated for RA and non-RA subjects and compared using Gray’s test.

Results: The study consisted of 813 RA and non-RA subjects (mean age 55.9 years, 68% female, 66% rheumatoid factor positive). Prior to RA incidence/non-RA index date, 53 RA and 66 non-RA subjects had a malignancy (p=0.22). The prevalence of hematologic malignancy was lower among RA subjects compared with non-RA subjects prior to the incidence/ index date, (n=0 vs n=7, p=0.015). Excluding patients with prior malignancies, the remaining RA patients were followed for a mean of 9.1 years (mean 10.3 years for non-RA) during which 109 RA and 94 non-RA subjects developed a malignancy. The cumulative incidence for hematologic malignancy was higher among RA than non-RA subjects (2.0% ± 0.6% vs 0.7% ± 0.3% at 10 years, p=0.009). There was no significant difference in the cumulative incidence of overall malignancy between RA and non-RA subjects (13.0% ± 1.5% vs 9.1% ±1.2% at 10 years, p=0.10). There was no significant difference in the rate of lung or colon cancer in RA subjects relative to non-RA subjects. The cumulative incidence of breast cancer was lower among RA subjects compared to non-RA in the first 10 years after diagnosis of RA (2.9% ± 0.8% vs 1.6% ± 0.7% at 10 years), but this difference did not achieve statistical significance (p=0.63).  Individuals diagnosed with RA more recently (1995-2007) were more likely to develop a hematologic malignancy compared with RA subjects diagnosed in earlier years (1980-1994) (hazard ratio [HR]: 2.28; 95% CI 0.95, 5.51). Similar changes were not seen over the same time period among subjects without RA.

Conclusion: Patients diagnosed with RA more recently appear to be at higher risk of developing a malignancy relative to patients diagnosed in earlier years. There was no significant difference in the rate of solid organ malignancies including breast, lung and colon cancer between RA and non-RA subjects in this population. The rate of hematologic malignancy is higher among patients with RA relative to non-RA subjects.


Disclosure:

K. Wright,
None;

C. S. Crowson,
None;

S. E. Gabriel,
None;

E. L. Matteson,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-time-trends-of-malignancy-in-rheumatoid-arthritis-a-population-based-study-1980-2007/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology